Sangamo Therapeutics, Inc (SGMO) SEC Filings — 2025
14 SEC filings for Sangamo Therapeutics, Inc (SGMO) in 2025.
Filings
- Sangamo's Revenue Plunges 98% Amid Mounting Losses, Going Concern Doubts — 10-Q · Nov 6, 2025
- Sangamo Therapeutics Faces Delisting Notice — 8-K · Oct 29, 2025
- Sangamo Therapeutics Reports Officer and Director Changes — 8-K · Sep 30, 2025
- Sangamo Therapeutics Reports Officer and Director Changes — 8-K · Sep 11, 2025
- Sangamo Therapeutics Files 8-K — 8-K · Sep 4, 2025
- Sangamo's Q2 Loss Widens to $75.2M Amid Revenue Decline — 10-Q · Aug 7, 2025
- Sangamo Therapeutics Files 8-K Report — 8-K · Jun 24, 2025
- Sangamo Therapeutics Announces Board Changes and Shareholder Votes — 8-K · Jun 16, 2025
- Sangamo Therapeutics Files 8-K — 8-K · May 13, 2025
- Sangamo Therapeutics Files Q1 2025 10-Q Report — 10-Q · May 12, 2025
- Sangamo Therapeutics Faces Delisting Concerns — 8-K · May 6, 2025
- Sangamo Therapeutics Executive Compensation Details — DEF 14A · Apr 30, 2025
- Sangamo Therapeutics, Inc 10-K Filing — 10-K · Mar 17, 2025
- Sangamo Therapeutics Relocates Principal Executive Offices — 8-K · Feb 6, 2025